BAM
ALT icon

Brave Asset Management’s Altimmune ALT Stock Holding History

Brave Asset Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$61.4K – 167
2024
Q3 		$61.4K Hold
10,000
– – 0.01% 154
2024
Q2 		$66.5K Hold
10,000
– – 0.02% 141
2024
Q1 		$102K Sell
10,000
-5,000
-33% -$50.9K 0.03% 141
2023
Q4 		$169K Hold
15,000
– – 0.05% 129
2023
Q3 		$39K Buy
+15,000
New +$43K 0.01% 144

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Brave Asset Management's ALT Position: Q4 2024 in Review

Brave Asset Management sold out of Altimmune (ALT) in Q4 2024, closing a stake of 10,000 shares — an estimated $61.4K sold.

Brave Asset Management first reported a position in ALT in Q3 2023 and held it in 5 quarters. The position peaked at $169K in Q4 2023. 182 funds tracked by Wall St. Rank hold ALT as of Q4 2024.

  • Brave Asset Management reported no remaining Altimmune position as of Q4 2024 after selling out during the quarter.
  • Brave Asset Management sold 10,000 Altimmune shares in Q4 2024, an estimated $61.4K.
  • Brave Asset Management first reported a position in Altimmune in Q3 2023 and held it in 5 quarters.
  • Brave Asset Management's Altimmune position peaked at $169K in Q4 2023.
  • 182 funds tracked by Wall St. Rank held Altimmune as of Q4 2024.

Based on Brave Asset Management's 13F filing for Q4 2024, filed 14 Jan 2025.